Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Suzanne M. Garland, Manjula Anagani, Neerja Bhatla, Sukanta Chatterjee, Sanjay Lalwani, Cecil Ross, Thomas Group, Jianxin Lin, Alain Luxembourg, Anuj Walia & Yingmei Tu. (2022) Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants. Human Vaccines & Immunotherapeutics 18:6.
Read now
Read now
Fangzhou Zhou, Wen Zhang, Hongning Cai & Yuan Cao. (2021) Portrayals of 2v, 4v and 9vHPV vaccines on Chinese social media: a content analysis of hot posts on Sina Weibo. Human Vaccines & Immunotherapeutics 17:11, pages 4433-4441.
Read now
Read now
Vu Dinh Thiem, Nguyen Dang Quang, Nguyen Hai Tuan, Kyeongmi Cheon, Nancy Gallagher, Alain Luxembourg, Thomas Group & Cyrus Badshah. (2021) Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial. Human Vaccines & Immunotherapeutics 17:7, pages 1980-1985.
Read now
Read now
Susanne K. Kjaer, Mari Nygård, Karin Sundström, Christian Munk, Sophie Berger, Mensur Dzabic, Katrin Elisabeth Fridrich, Marianne Waldstrøm, Sveinung Wergeland Sørbye, Oliver Bautista, Thomas Group & Alain Luxembourg. (2021) Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up. Human Vaccines & Immunotherapeutics 17:4, pages 943-949.
Read now
Read now
Hui Xu, Yu Ling, Yuan Xi, Hong Ma, Hao Wang, Hui-Min Hu, Qi Liu, Yu-Mei Li, Xu-Tao Deng, Shi-Xing Yang, Eric Delwart & Wen Zhang. (2019) Viral metagenomics updated the prevalence of human papillomavirus types in anogenital warts. Emerging Microbes & Infections 8:1, pages 1291-1299.
Read now
Read now
Articles from other publishers (32)
Jaime Restrepo, Teobaldo Herrera, Rudiwilai Samakoses, Julio C. Reina, Punnee Pitisuttithum, Angels Ulied, Linda-Gail Bekker, Edson D. MoreiraJrJr, Sven-Eric Olsson, Stan L. Block, Luciano S. Hammes, Fabio Laginha, Alex Ferenczy, Robert Kurman, Brigitte M. Ronnett, Mark Stoler, Oliver Bautista, Nancy E. Gallagher, Gino Salituro, Min Ye & Alain Luxembourg. (2023) Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety. Pediatrics 152:4.
Crossref
Crossref
Michela Buttà, Nicola Serra, Vera Panzarella, Teresa Maria Assunta Fasciana, Giuseppina Campisi & Giuseppina Capra. (2023) Orogenital Human Papillomavirus Infection and Vaccines: A Survey of High- and Low-Risk Genotypes Not Included in Vaccines. Vaccines 11:9, pages 1466.
Crossref
Crossref
Miriam Reuschenbach, John Doorbar, Marta del Pino, Elmar A. Joura, Caroline Walker, Rosybel Drury, Andreas Rauscher & Alfred J. Saah. (2023) Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer. Vaccine.
Crossref
Crossref
Katrina M. Nolan, Brent Seaton, Joseph Antonello, Yuhua Zhang, Lauren Cook, Krystyn Delfino, Leonard J. Rubinstein, Kyeongmi Cheon, Thomas Group, Alain Luxembourg & Sheri Dubey. (2023) Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types. mSphere 8:2.
Crossref
Crossref
Kunal Saxena, Baanie Sawhney, Soham Yande, Niranjan Kathe & Sagnik Chatterjee. (2023) The Burden of Cervical Conization in Privately Insured Young and Mid-Adult Women in the United States. Vaccines 11:4, pages 804.
Crossref
Crossref
Marte Hernández Porras & Jorge Alejandro Vázquez Narváez. (2023) Virus del papiloma. Revista Latinoamericana de Infectología Pediátrica 36:4, pages 151-154.
Crossref
Crossref
Jingyi Fan, Shengbin Jin, Lachlan Gilmartin, Istvan Toth, Waleed M. Hussein & Rachel J. Stephenson. (2022) Advances in Infectious Disease Vaccine Adjuvants. Vaccines 10:7, pages 1120.
Crossref
Crossref
Huakun Lv, Shenyu Wang, Zhenzhen Liang, Wei Yu, Chuanfu Yan, Yingping Chen, Xiaosong Hu, Rong Fu, Minghuan Zheng, Thomas Group, Alain Luxembourg, Xueyan Liao & Zhiping Chen. (2022) Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: A phase 3 open-label study. Vaccine 40:23, pages 3263-3271.
Crossref
Crossref
Anna R. Giuliano. (2022) Initiation of three complementary international studies investigating prevalence of oral HPV infection, burden of HPV-related head and neck disease, and efficacy of 9-valent HPV vaccination against oral HPV persistent infection. Contemporary Clinical Trials 115, pages 106629.
Crossref
Crossref
Anna R. Giuliano, Timothy Wilkin, Oliver M. Bautista, Kyeongmi Cheon, Laurie Connor, Sheri Dubey, Alain Luxembourg, Sonali Rawat, Anita Shaw, Christine Velicer, Neika Vendetti & Yingmei Tu. (2022) Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men. Contemporary Clinical Trials 115, pages 106592.
Crossref
Crossref
Vincent Daniels, Kunal Saxena, Oscar Patterson-Lomba, Andres Gomez-Lievano, Alfred Saah, Alain Luxembourg, Christine Velicer, Ya-Ting Chen & Elamin Elbasha. (2022) Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom. Vaccine 40:14, pages 2173-2183.
Crossref
Crossref
Cui Zhang, Zengqiang Kou, Renpeng Li, Feng Ji, Xiaojuan Lin, Aiqiang Xu, Yanyan Song & Zexin Tao. (2021) Genomic diversity of human papillomavirus type 6 from patients with condyloma acuminatum in Eastern China. Infection, Genetics and Evolution, pages 105146.
Crossref
Crossref
Vimalanand S Prabhu, Craig S Roberts, Smita Kothari & Linda Niccolai. (2021) Median Age at HPV Infection Among Women in the United States: A Model-Based Analysis Informed by Real-world Data. Open Forum Infectious Diseases 8:7.
Crossref
Crossref
Hedy Teppler, Oliver Bautista, Sheryl Flores, Jennifer McCauley & Alain Luxembourg. (2021) Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals. Contemporary Clinical Trials 105, pages 106403.
Crossref
Crossref
Elmar A. Joura, Angels Ulied, Corinne Vandermeulen, Milagrosa Rua Figueroa, Ilkka Seppä, Juan José Hernandez Aguado, Anitta Ahonen, Olaf Reich, Miia Virta, Antonino Perino, Merce Peris Tuser, Klaus Peters, Massimo Origoni, Francesco Raspagliesi, Wiebren A.A. Tjalma, Philippe Tummers, Linn Woelber, Pekka Nieminen, Pierre van Damme, Jalid Sehouli, Gabriel Fiol Ruiz, Sara Brucker, Tanja Fehm, Kyeongmi Cheon, Sonali Rawat, Alain Luxembourg & Frederick Wittke. (2021) Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study. Vaccine 39:20, pages 2800-2809.
Crossref
Crossref
Margaret Stanley, Elmar Joura, Glorian P. Yen, Smita Kothari, Alain Luxembourg, Alfred Saah, Anuj Walia, Gonzalo Perez, Hanane Khoury, Danielle Badgley & Darron R. Brown. (2021) Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines. Vaccine 39:16, pages 2214-2223.
Crossref
Crossref
Darron R. Brown, Elmar A. Joura, Glorian P. Yen, Smita Kothari, Alain Luxembourg, Alfred Saah, Anuj Walia, Gonzalo Perez, Hanane Khoury, Danielle Badgley & Margaret Stanley. (2021) Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence. Vaccine 39:16, pages 2224-2236.
Crossref
Crossref
Jacob BornsteinSurita RouxLone Kjeld PetersenLi-Min HuangSimon R. DobsonPunnee PitisuttithumJavier Diez-DomingoAndrea SchillingHany AriffinRichard TytusRichard RuppShelly SendersEli EngelDaron FerrisYae-Jean KimYoung Tae KimZafer Kurugol, Oliver Bautista, Katrina M. Nolan, Sandhya Sankaranarayanan, Alfred Saah & Alain Luxembourg. (2021) Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine. Pediatrics 147:1.
Crossref
Crossref
Zhuhang Huang, Jianfeng He, Jiali Su, Zhiqiang Ou, Guixiu Liu, Rong Fu, Qiong Shou, Minghuan Zheng, Thomas Group, Alain Luxembourg, Xueyan Liao & Jikai Zhang. (2021) Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study. Vaccine 39:4, pages 760-766.
Crossref
Crossref
Ishita Gupta, Gheyath K. Nasrallah, Anju Sharma, Ayesha Jabeen, Maria K. Smatti, Hamda A. Al-Thawadi, Ali A. Sultan, Moussa Alkhalaf, Semir Vranic & Ala-Eddin Al Moustafa. (2020) Co-prevalence of human Papillomaviruses (HPV) and Epstein–Barr virus (EBV) in healthy blood donors from diverse nationalities in Qatar. Cancer Cell International 20:1.
Crossref
Crossref
Daron G. Ferris, Darron R. Brown, Anna R. Giuliano, Evan Myers, Elmar A. Joura, Suzanne M. Garland, Susanne K. Kjaer, Gonzalo Perez, Alfred Saah, Alain Luxembourg & Christine Velicer. (2020) Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Papillomavirus Research 10, pages 100202.
Crossref
Crossref
Ishita Gupta, Lina Ghabreau, Hamda Al-Thawadi, Amber Yasmeen, Semir Vranic, Ala-Eddin Al Moustafa & Mohammed I. Malki. (2020) Co-incidence of Human Papillomaviruses and Epstein–Barr Virus Is Associated With High to Intermediate Tumor Grade in Human Head and Neck Cancer in Syria. Frontiers in Oncology 10.
Crossref
Crossref
Susanne K. Kjaer, Mari Nygård, Karin Sundström, Joakim Dillner, Laufey Tryggvadottir, Christian Munk, Sophie Berger, Espen Enerly, Maria Hortlund, Ágúst Ingi Ágústsson, Kaj Bjelkenkrantz, Katrin Fridrich, Ingibjorg Guðmundsdóttir, Sveinung Wergeland Sørbye, Oliver Bautista, Thomas Group, Alain Luxembourg, J. Brooke Marshall, David Radley, Yi Shen Yang, Cyrus Badshah & Alfred Saah. (2020) Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine 23, pages 100401.
Crossref
Crossref
Xiangfan Chen, Hong Yan, Yingnan Cao, Shiyue Li, Ningxi Yang & Xiaoyan Li. (2020) Epidemiological investigation on the cervical health of lesbians in Beijing, China. Journal of International Medical Research 48:2, pages 030006051988975.
Crossref
Crossref
Jorma Paavonen, Suzanne M. Garland & David Jenkins. 2020. Human Papillomavirus. Human Papillomavirus
299
325
.
Silvia de Sanjose, Maria Brotons, D Scott LaMontagne & Laia Bruni. (2019) Human papillomavirus vaccine disease impact beyond expectations. Current Opinion in Virology 39, pages 16-22.
Crossref
Crossref
Anna R. Giuliano, Elmar A. Joura, Suzanne M. Garland, Warner K. Huh, Ole-Erik Iversen, Susanne K. Kjaer, Alex Ferenczy, Robert J. Kurman, Brigitte M. Ronnett, Mark H. Stoler, Oliver M. Bautista, Erin Moeller, Michael Ritter, Christine Shields & Alain Luxembourg. (2019) Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecologic Oncology 154:1, pages 110-117.
Crossref
Crossref
Masaru Sakamoto, Etsuko Miyagi, Yukari Sumi, Kohzo Aisaka, Naohiko Kuno, Hiroshi Nagano, Saiko Asahara, Shi Rong Han, Akira Wakana, Shinya Murata, Miyuki Sawata & Yoshiyuki Tanaka. (2019) Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women. Journal of Infection and Chemotherapy 25:7, pages 520-525.
Crossref
Crossref
L. David Wise, Jayanthi J. Wolf & Lisa M. Plitnick. (2018) Evaluation of a 9-valent HPV vaccine in Sprague-Dawley rats: Nonclinical studies assessing general, reproductive, and developmental toxicity. Vaccine 36:43, pages 6401-6407.
Crossref
Crossref
Hamda Al-Thawadi, Lina Ghabreau, Tahar Aboulkassim, Amber Yasmeen, Semir Vranic, Gerald Batist & Ala-Eddin Al Moustafa. (2018) Co-Incidence of Epstein–Barr Virus and High-Risk Human Papillomaviruses in Cervical Cancer of Syrian Women. Frontiers in Oncology 8.
Crossref
Crossref
Farhan S. Cyprian, Halema F. Al-Farsi, Semir Vranic, Saghir Akhtar & Ala-Eddin Al Moustafa. (2018) Epstein–Barr Virus and Human Papillomaviruses Interactions and Their Roles in the Initiation of Epithelial–Mesenchymal Transition and Cancer Progression. Frontiers in Oncology 8.
Crossref
Crossref
Rohan Ameratunga, Daman Langguth & David Hawkes. (2018) Perspective: Scientific and ethical concerns pertaining to animal models of autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA). Autoimmunity Reviews 17:5, pages 435-439.
Crossref
Crossref